Christina Smith

Christina Smith

Auto-generated profile, based on publicly available information

Christina Smith

California Institute of Technology

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 October 2018 in Chemical Society Reviews
Verified
Journal Article
Closed access
PDF file
PAPatrick J. Almhjell
Patrick J. Almhjell
CBChristina E. Boville
Christina E. Boville
FAFrances H. Arnold
Frances H. Arnold
This tutorial review covers contemporary case studies of successful protein engineering to provide new noncanonical amino acid synthases, with emphasis on methods, outcomes, and mechanistic insights.

15 March 2013 in Chemical Society Reviews
Verified
Journal Article
Closed access
PDF file
XWXiaohui Wang
Xiaohui Wang
CSChristina Smith
Christina Smith
HYHang Yin
Hang Yin
Toll-like receptors (TLRs) are type I transmembrane proteins that are key regulators of both innate and adaptive immune responses. To protect the host from viral and bacterial threats, TLRs trigger a pro-inflammatory immune response by detecting pathogen and danger associated molecular patterns. Considerable evidence has accumulated to show that the dysregulation of TLR signaling contributes to the development and progression of numerous diseases. Therefore, TLRs are emerging as important drug discovery targets. Currently, there is great interest in the development of TLR small molecule modulators for interrogating TLR signaling and treating diseases caused by TLR signaling malfunctions. In this tutorial review, we will outline methods for the discovery of TLR small molecule modulators and the up-to-date progress in this field. Small molecules targeting TLRs not only provide an opportunity to identify promising drug candidates, but also unveil knowledge regarding TLR signaling pathways.

1 March 2017 in Cell Chemical Biology
Verified
Journal Article
Closed access
CSChristina E. Smith
Christina E. Smith
SSSubada Soti
Subada Soti
TJTorey A. Jones
Torey A. Jones
ANAkihisa Nakagawa
Akihisa Nakagawa
DXDing Xue
Ding Xue
HYHang Yin
Hang Yin

13 April 2018 in The Journal of Organic Chemistry
Verified
Journal Article
Closed access
CBChristina E. Boville
Christina E. Boville
DRDavid K. Romney
David K. Romney
PAPatrick J. Almhjell
Patrick J. Almhjell
MSMichaela Sieben
Michaela Sieben
FAFrances H. Arnold
Frances H. Arnold

12 October 2018 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
CBChristina E. Boville
Christina E. Boville
RSRemkes A. Scheele
Remkes A. Scheele
PKPhilipp Koch
Philipp Koch
SBSabine Brinkmann‐Chen
Sabine Brinkmann‐Chen
ABAndrew R. Buller
Andrew R. Buller
FAFrances H. Arnold
Frances H. Arnold

8 April 2013 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
XWXiaohui Wang
Xiaohui Wang
PGPeter Grace
Peter Grace
MPMichael N. Pham
Michael N. Pham
KCKui Cheng
Kui Cheng
KSKeith A. Strand
Keith A. Strand
HYHang Yin
Hang Yin
Rifampin has been used for the treatment of bacterial infections for many years. Clinically, rifampin has been found to possess immunomodulatory effects. However, the molecular target responsible for the immunosuppressive effects of rifampin is not known. Herein, we show that rifampin binds to myeloid differentiation protein 2 (MD‐2), the key coreceptor for innate immune TLR4. Rifampin blocked TLR4 signaling induced by LPS, including NF‐ k B activation and the overproduction of proinflammatory mediators nitric oxide, interleukin 1 β, and tumor necrosis factor α in mouse microglia BV‐2 cells and macrophage RAW 264.7 cells. Rifampin's inhibition of TLR4 signaling was also observed in immunocompetent rat primary macrophage, microglia, and astrocytes. Further, we show that rifampin (75 or 100 mg/kg b.i.d. for 3 d, intraperitoneal) suppressed allodynia induced by chronic constriction injury of the sciatic nerve and suppressed nerve injury‐induced activation of microglia. Our findings indicate that MD‐2 is a important target of rifampin in its inhibition of innate immune function and contributes to its clinically observed immune‐suppressive effect. The results also suggest that rifampin may be repositioned as an agent for the treatment of neuropathic pain.—Wang, X., Grace, P. M., Pham, M. N., Cheng, K., Strand, K. A., Smith, C., Li, J., Watkins, L. R., Yin, H. Rifampin inhibits Toll‐like receptor 4 signaling by targeting myeloid differentiation protein 2 and attenuates neuropathic pain. FASEB J. 27, 2713‐2722 (2013). www.fasebj.org